Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases

J Med Chem. 2012 Mar 22;55(6):2846-57. doi: 10.1021/jm201758g. Epub 2012 Mar 9.

Abstract

A novel series of N(4)-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance. The selected compound (19a) showed excellent inhibitory activity toward HER-1/HER-2 tyrosine kinases with selectivity over 20 other kinases and inhibited the proliferation of both cancer cell types: lapatinib-sensitive cell lines (SK-Br3, MDA-MB-175, and N87) and lapatinib-resistant cell lines (MDA-MB-453, H1781, and H1975). The excellent pharmacokinetic profiles of 19a in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer.

MeSH terms

  • Acrylamides / chemical synthesis*
  • Acrylamides / pharmacokinetics
  • Acrylamides / pharmacology
  • Animals
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Drug Resistance, Neoplasm
  • Drug Screening Assays, Antitumor
  • ErbB Receptors / antagonists & inhibitors*
  • Female
  • Humans
  • Lapatinib
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Mice
  • Mice, Inbred ICR
  • Models, Molecular
  • Mutation
  • Oxazoles / chemical synthesis*
  • Oxazoles / pharmacokinetics
  • Oxazoles / pharmacology
  • Pyrimidines / chemical synthesis*
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / pharmacology
  • Quinazolines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / genetics
  • Structure-Activity Relationship

Substances

  • Acrylamides
  • Antineoplastic Agents
  • N-((2-(4-amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide
  • Oxazoles
  • Pyrimidines
  • Quinazolines
  • Lapatinib
  • EGFR protein, human
  • ERBB2 protein, human
  • ErbB Receptors
  • Receptor, ErbB-2